HRP20160518T1 - Postupci za proizvodnju farmaceutske djelatne tvari - Google Patents

Postupci za proizvodnju farmaceutske djelatne tvari Download PDF

Info

Publication number
HRP20160518T1
HRP20160518T1 HRP20160518TT HRP20160518T HRP20160518T1 HR P20160518 T1 HRP20160518 T1 HR P20160518T1 HR P20160518T T HRP20160518T T HR P20160518TT HR P20160518 T HRP20160518 T HR P20160518T HR P20160518 T1 HRP20160518 T1 HR P20160518T1
Authority
HR
Croatia
Prior art keywords
process according
compound
formula
alcoholic solvent
rani
Prior art date
Application number
HRP20160518TT
Other languages
English (en)
Inventor
Frans Therkelsen
Michael Harold Rock
Svend Treppendahl
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HRP20160518T1 publication Critical patent/HRP20160518T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines

Claims (14)

1. Postupak pripreme spoja formule IV, [image] koji obuhvaća korake: (a) miješanje (6-fluoro-1H-indol-3-il)acetonitrila, NH3 u vodi i prijelaznog metalnog katalizatora u alkoholnom otapalu; i (b) hidrogeniranje smjese s H2.
2. Postupak prema zahtjevu 1, gdje je prijelazni metalni katalizator RaNi.
3. Postupak prema zahtjevu 1, gdje je alkoholno otapalo metanol.
4. Postupak prema bilo kojem od zahtjeva 1-3, gdje se hidrogeniranje provodi pri tlaku od 250000 paskala (2.5 bara) kroz 16 sati.
5. Postupak prema bilo kojem od zahtjeva 1-4, gdje se hidrogeniranje provodi na temperaturi od 55°C do 65°C.
6. Postupak prema zahtjevu 2, gdje se RaNi koristi kao katalizator u obliku metalne spužve.
7. Postupak prema zahtjevu 2 ili 6, gdje je nominalni sastav aluminija u RaNi 5% i medijan veličine čestica RaNi je 33 mikrona.
8. Postupak prema bilo kojem od zahtjeva 1-7, gdje je NH3 prisutan u vodenoj otopini u koncentraciji od 25%.
9. Postupak prema bilo kojem od prethodnih zahtjeva, dalje obuhvaća pročišćavanje spoja formule IV, pročišćavanje obuhvaća: (a) otapanje spoja formule IV u alkoholnom otapalu; (b) dodavanje otopine L(+)-vinske kiseline; i (c) hvatanje vinske kiseline u obliku taloga.
10. Postupak prema zahtjevu 9, gdje je alkoholno otapalo metanol.
11. Postupak prema zahtjevu 9 ili 10, gdje se etil acetat koristi s alkoholnim otapalom.
12. Postupak prema bilo kojem od prethodnih zahtjeva, dalje obuhvaća reakciju spoja Formule IV da se formira spoj formule I, spajanjem amina s 3-(2,2,3,3-tetrafluoropropoksi)benzaldehidom u prisutnosti otapala, nakon čega slijedi redukcija iminske veze pomoću reducensa [image]
13. Postupak prema zahtjevu 12, gdje je reducens natrijev borohidrid.
14. Postupak prema zahtjevu 12 ili 13, dalje obuhvaća pretvorbu spoja formule I u njegovu HCl sol salt putem dodavanja HCl, nakon čega po izboru slijedi pročišćavanje dobivene soli.
HRP20160518TT 2009-12-23 2016-05-16 Postupci za proizvodnju farmaceutske djelatne tvari HRP20160518T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28953009P 2009-12-23 2009-12-23
PCT/DK2010/050348 WO2011076212A2 (en) 2009-12-23 2010-12-20 Processes for the manufacture of a pharmaceutically active agent
EP10803222.8A EP2516394B1 (en) 2009-12-23 2010-12-20 Processes for the manufacture of a pharmaceutically active agent

Publications (1)

Publication Number Publication Date
HRP20160518T1 true HRP20160518T1 (hr) 2016-06-03

Family

ID=43567689

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160518TT HRP20160518T1 (hr) 2009-12-23 2016-05-16 Postupci za proizvodnju farmaceutske djelatne tvari

Country Status (37)

Country Link
US (3) US8461353B2 (hr)
EP (1) EP2516394B1 (hr)
JP (2) JP5864435B2 (hr)
KR (2) KR101873182B1 (hr)
CN (2) CN102656146B (hr)
AR (1) AR079580A1 (hr)
AU (1) AU2010335659B2 (hr)
BR (1) BR112012015749A2 (hr)
CA (1) CA2785440C (hr)
CL (1) CL2012001725A1 (hr)
CR (1) CR20120316A (hr)
CY (1) CY1118032T1 (hr)
DK (1) DK2516394T3 (hr)
DO (1) DOP2012000170A (hr)
EA (1) EA021440B1 (hr)
ES (1) ES2575666T3 (hr)
GE (1) GEP20146078B (hr)
HK (2) HK1174921A1 (hr)
HR (1) HRP20160518T1 (hr)
HU (1) HUE028806T2 (hr)
IL (2) IL220329A (hr)
MA (1) MA33945B1 (hr)
ME (1) ME02401B (hr)
MX (1) MX2012007078A (hr)
MY (1) MY159251A (hr)
NZ (2) NZ600639A (hr)
PL (1) PL2516394T3 (hr)
PT (1) PT2516394E (hr)
RS (1) RS54820B1 (hr)
SG (1) SG181910A1 (hr)
SI (1) SI2516394T1 (hr)
SM (1) SMT201600166B (hr)
TN (1) TN2012000279A1 (hr)
TW (1) TW201139370A (hr)
UA (1) UA111584C2 (hr)
WO (1) WO2011076212A2 (hr)
ZA (1) ZA201305936B (hr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
JO3639B1 (ar) * 2014-07-04 2020-08-27 H Lundbeck As صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
CN104130174A (zh) * 2014-07-30 2014-11-05 天津市斯芬克司药物研发有限公司 一种吲唑衍生物及其制备方法
CN105175307A (zh) * 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途
TW201630881A (zh) 2014-12-12 2016-09-01 H 朗德貝克公司 用於生產艾達魯吡啶之方法
CN104529865B (zh) * 2014-12-12 2017-02-01 广东东阳光药业有限公司 苄胺类衍生物及其在药物上的应用
MA41148A (fr) * 2014-12-12 2017-10-17 H Lundbeck As Procédé de fabrication d'idalopirdine
CN108271369A (zh) * 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
JP2019513742A (ja) 2016-04-08 2019-05-30 ハー・ルンドベック・アクチエゼルスカベット イミンの水素化によるイダロピルジンの製造方法
EP3333154A1 (en) * 2016-12-07 2018-06-13 Sandoz Ag Crystalline form of a selective 5-ht6 receptor antagonist

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3042685A (en) 1962-07-03 Process of making g-fluoro tryptamine
GB846675A (en) 1958-04-18 1960-08-31 Lab Francais Chimiotherapie Process for the production of a tryptamine derivative
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
DE69416697T2 (de) 1993-12-28 1999-09-09 Rhone Poulenc Fibres Verfahren zur katalytischer hydrogenierung von nitrilen zu aminen in anwesenheit eines dosierten raney nickel katalysators
EP0737101B1 (fr) 1993-12-28 1998-09-23 RHODIA FIBER & RESIN INTERMEDIATES Procede de preparation d'un catalyseur d'hydrogenation de nitriles en amines et application de ce catalyseur en hydrogenation
US5869653A (en) 1997-10-30 1999-02-09 Air Products And Chemicals, Inc. Hydrogenation of nitriles to produce amines
KR20000069831A (ko) 1997-10-31 2000-11-25 요트.게.아. 롤페즈 구성 신호에 대한 잡음 추가를 통한 엘피씨 원칙에 따라 인코딩된 음성의 오디오 표현을 위한 방법 및 장치
US6156694A (en) 1998-11-05 2000-12-05 E. I. Dupont De Nemours & Company Raney cobalt catalyst and a process for hydrogenating organic compounds using said catalyst
AU2002303094B2 (en) 2001-03-29 2006-11-23 Eli Lilly And Company N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor
US7084154B2 (en) * 2003-02-11 2006-08-01 Pharmacopeia Drug Disclovery, Inc. 2-(aminomethyl) arylamide analgesics
FR2866335B1 (fr) 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
JP2006169113A (ja) * 2004-12-10 2006-06-29 Dainippon Sumitomo Pharma Co Ltd インドール類の合成方法および合成中間体
WO2007070796A1 (en) * 2005-12-15 2007-06-21 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
JO2704B1 (en) * 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
WO2010036362A1 (en) * 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors
CN101531624A (zh) 2009-04-08 2009-09-16 大连凯飞精细化工有限公司 6-氟吲哚-3-乙腈的合成方法
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent

Also Published As

Publication number Publication date
MY159251A (en) 2016-12-30
DK2516394T3 (en) 2016-06-13
US20150080584A1 (en) 2015-03-19
KR101796330B1 (ko) 2017-11-09
EP2516394B1 (en) 2016-03-16
ME02401B (me) 2016-09-20
TW201139370A (en) 2011-11-16
US20110152539A1 (en) 2011-06-23
NZ600639A (en) 2014-07-25
SI2516394T1 (sl) 2016-07-29
IL220329A (en) 2016-03-31
KR20170125417A (ko) 2017-11-14
PL2516394T3 (pl) 2016-09-30
CN103694161A (zh) 2014-04-02
GEP20146078B (en) 2014-04-10
HUE028806T2 (en) 2017-01-30
CA2785440C (en) 2018-05-01
JP6195605B2 (ja) 2017-09-13
CY1118032T1 (el) 2017-05-17
DOP2012000170A (es) 2012-08-31
RS54820B1 (sr) 2016-10-31
US20130245281A1 (en) 2013-09-19
AU2010335659B2 (en) 2015-05-21
PT2516394E (pt) 2016-06-07
CA2785440A1 (en) 2011-06-30
CL2012001725A1 (es) 2012-11-30
EA201290552A1 (ru) 2012-12-28
WO2011076212A3 (en) 2011-08-11
US8461353B2 (en) 2013-06-11
HK1174921A1 (en) 2013-06-21
EA021440B1 (ru) 2015-06-30
SG181910A1 (en) 2012-08-30
JP5864435B2 (ja) 2016-02-17
CN102656146B (zh) 2014-12-17
AU2010335659A1 (en) 2012-07-05
KR101873182B1 (ko) 2018-06-29
KR20120112480A (ko) 2012-10-11
IL231141A (en) 2016-03-31
ES2575666T3 (es) 2016-06-30
MA33945B1 (fr) 2013-01-02
IL231141A0 (en) 2014-03-31
WO2011076212A2 (en) 2011-06-30
CN103694161B (zh) 2015-09-09
CN102656146A (zh) 2012-09-05
TN2012000279A1 (en) 2013-12-12
US9382205B2 (en) 2016-07-05
JP2016117734A (ja) 2016-06-30
ZA201305936B (en) 2015-09-30
UA111584C2 (uk) 2016-05-25
BR112012015749A2 (pt) 2015-09-15
IL220329A0 (en) 2012-08-30
CR20120316A (es) 2012-08-16
SMT201600166B (it) 2016-07-01
US8901318B2 (en) 2014-12-02
NZ625798A (en) 2014-10-31
JP2013515683A (ja) 2013-05-09
EP2516394A2 (en) 2012-10-31
MX2012007078A (es) 2012-07-20
HK1196352A1 (en) 2014-12-12
AR079580A1 (es) 2012-02-01

Similar Documents

Publication Publication Date Title
HRP20160518T1 (hr) Postupci za proizvodnju farmaceutske djelatne tvari
HRP20191249T1 (hr) Procesi za pripremu (s)-1-(3-etoksi-4metoksifenil)-2-metansulfoniletilamina
IL198902A0 (en) Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of the derivatives
HRP20150885T1 (hr) Postupak za pripremu 4-{4-[({[4-kloro-3-(trifluorometil)-fenil]amino}karbonil)amino]-3-fluorofenoksi}-n-metilpiridin-2-karboksamida, njegovih soli i monohidrata
WO2011017139A3 (en) Preparation of diesel oxidation catalyst via deposition of colloidal nanoparticles
HRP20180948T1 (hr) Postupak za proizvodnju aminokiselinskih spojeva
WO2012070069A3 (en) A process for preparation of albendazole
MX2009006207A (es) Proceso para la obtencion del acido 1-(2-etil-butil)-ciclohexanoca rboxilico.
JP6719527B2 (ja) アゾキシストロビン中間体の調製方法
NZ589350A (en) Novel [F-18]-labelled L-glutamic acid- and L-glutamine derivatives (I), use thereof and method for their production
WO2007056041A3 (en) Method of producing a nickel salt solution
EP2537856A4 (en) PROCESS FOR THE PREPARATION OF ATOSIBAN ACETATE
RU2013122694A (ru) Способ получения сульфата-нитрата аммония
CA2608553A1 (en) Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts
WO2011154333A3 (de) Verfahren zur herstellung kristalliner 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)-undecandisäure und die verwendung zur herstellung von primovist®
WO2012164242A8 (en) Process for the preparation of paliperidone
CN105566162A (zh) 利匹韦林中间体的制备工艺
CN102372316A (zh) 吸附有机物的净水剂
NZ612592A (en) Process for the enzymatic synthesis of (7s)-1-(3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl) n-methyl methanamine, and application in the synthesis of ivabradine and salts thereof
WO2011091677A1 (zh) 阿利吉仑中间体3-氨基-2,2-二甲基丙酰胺的制备方法
CN106810452A (zh) 一种盐酸西那卡塞的制备方法
WO2008142706A3 (en) Novel process for the synthesis of pioglitazone and its salts thereof
CA2820413C (en) Method for synthesising substituted aminocyclohexanone derivatives
CN103086897A (zh) 一种水合肼还原邻-硝基二苯醚制备邻-氨基二苯醚的方法
NZ593585A (en) Crystalline forms of vorinostat (suberoylanilide hydroxamic acid)